Kos Biotechnology Partners Invests in Fathom Therapeutics’ $55M Series A to Advance AI-Driven Drug Discovery

The investment, made through Kos's inaugural life sciences fund, Kos BioVentures, will support Fathom's development of an AI-driven drug discovery platform combining quantum chemistry, physics-based molecular simulations, and artificial intelligence.

Kos Biotechnology Partners has invested in Fathom Therapeutics as part of the biotechnology company's oversubscribed $55 million Series A financing, led by Sutter Hill Ventures. The investment, made through Kos's inaugural life sciences fund, Kos BioVentures, will support Fathom's development of an AI-driven drug discovery platform combining quantum chemistry, physics-based molecular simulations, and artificial intelligence.

Fathom Therapeutics is developing its proprietary Microcosmos platform to predict how proteins move and interact with drug molecules at atomic resolution. The technology combines physics-based simulations with AI to model molecular interactions and identify potential drug candidates, including against biological targets that have historically been considered difficult to address through conventional drug discovery approaches.

Founded by computational scientists led by CEO Dr. Huafeng Xu, Fathom Therapeutics aims to develop next-generation small-molecule medicines using computational methods. Its co-founders include Yujie Wu, PhD, Chief Technology Officer, and Jesús Izaguirre, PhD, Chief Computational Scientist.

The founding team's research includes contributions to the development of the Anton supercomputer and computational methods used to predict protein-drug interactions. The company also brings drug development experience across its broader leadership team.

Commenting on the investment, Dr. Simos Simeonidis, co-founder and managing partner of Kos Biotechnology Partners, said Fathom's expertise in quantum chemistry and AI could help address biological targets that have historically been considered undruggable. He added that the firm would support the company in advancing its technology and translating its potential into therapeutic applications.

Dr. Huafeng Xu said the company looks forward to working with Kos and its investment team as it advances its drug development objectives.

Alex Tzoukas, co-founder and managing partner of Kos Biotechnology Partners, said the investment reflects the firm's focus on technologies that improve drug discovery productivity and address previously inaccessible biological targets. He also highlighted the intersection of computational science, AI, and experimental biology as an emerging area in biopharmaceutical innovation.

Based in New York and Athens, Greece, Kos Biotechnology Partners manages $125 million in assets and invests across different stages of development in therapeutic breakthroughs, biodefense, and technology-enabled pharmaceutical services. The Fathom investment adds to its portfolio of life sciences companies.

Stay tuned for more such updates on Digital Health News